Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing targeted cancer immunotherapies. The company engineers and develops next-generation bispecific antibodies – TandAbs ® - that bind with high specificity and affinity to certain cancer cells and direct the most potent cells of the human immune defense arsenal, Natural Killer cells (NK-cells) or T-cells, to attack and kill these cancer cells.
Affimed’s lead development candidate AFM13 is an NK-cell TandAb. It targets CD30 malignancies, notably Hodgkin Lymphoma (HL) and directs NK-cells to eliminate tumor cells by specifically attaching to their CD16A receptor. Promising clinical results from a phase 1 safety study using this first-in-class approach have been obtained. Affimed’s second clinical stage candidate AFM11 is a T-cell TandAb. It targets CD19 malignancies, notably non-Hodgkin Lymphoma (NHL), and directs T-cells to destroy the cancer cells by specifically attaching to their CD3 receptor. The company has another T-cell TandAb product entering preclinical development that targets Epidermal Growth Factor Receptor variant III (EGFRvIII) and directs T-cells to destroy the tumor cells. All three products have been discovered in-house, and Affimed retains full rights to its internal pipeline.
Affimed generates its pipeline of product candidates from three proprietary next-generation antibody engineering technologies: